Szabi studied international business at the Corvinus University of Budapest. A serial entrepreneur, he co-founded Turbine in 2015 after helping launch a cybersecurity startup that was subsequently acquired. He later served as Chief Strategy Officer at The Medical Futurist, leading thought leadership initiatives before returning his focus to Turbine's quest for virtual cells. Although entering the field with what he describes as "outsider energy", Szabi has steered Turbine through multiple top pharma partnerships - including Bayer, AstraZeneca, and Merck - and several financing rounds, all leading up to this latest $25 million Series B milestone.

A computer scientist turned biochemist, Kristóf's dream is to turn biology into an engineering discipline, enabling science to model human tissues and organs as efficiently as we do for passenger vehicles. Named one of the 35 Innovators under 35 in 2018 by MIT Tech Review Europe, Kristóf invented Turbine's original method of simulating human cellular response to therapeutic perturbations and is leading the research efforts to build Virtual Assays that make ever more hidden biology available for biopharma R&D to explore.

As a medical doctor specializing in cancer research at some of the world's top research institutes, Daniel helps design innovative and durable treatments against cancer by converting our platform's computational results into clinical interpretations. His main responsibility lies in understanding scientific and medical challenges, to then guide our team of biologists, translational and data scientists in generating novel findings to move better treatments to patients.